医学
心肌炎
心包炎
重症监护医学
心脏毒性
疾病
癌症
急性心包炎
心脏病
内科学
心脏病学
心力衰竭
癌症治疗
多学科方法
梅德林
免疫系统
冠心病
免疫疗法
肿瘤科
生物信息学
疾病管理
作者
Joerg Herrmann,Ana Barac,Joseph R. Carver,Richard K. Cheng,Andrés J. Daniele,Susan Dent,Elena Deych,Dae Hyun Lee,Daniel J. Lenihan,Darryl P. Leong,Jennifer Liu,Teresa López‐Fernández,Alexander R Lyon,Michael G. Fradley,Ariane Vieira Scarlatelli Macedo,Meghan J. Mooradian,Anju Nohria,Charles Porter,Tienush Rassaf,Giselle Alexandra Suero‐Abreu
出处
期刊:JAMA Oncology
[American Medical Association]
日期:2025-11-13
卷期号:12 (1): 90-90
被引量:14
标识
DOI:10.1001/jamaoncol.2025.4543
摘要
Importance: The introduction of immune checkpoint inhibitor (ICI) therapy has improved cancer outcomes but at the cost of adverse events, mainly related to the immune system. Cardiovascular (CV) toxic effects, and especially myocarditis, are of particular concern and are the subject of this position statement by the International Cardio-Oncology Society with representation of experts from oncology, hematology, and cardiology. Observations: CV toxic effects of ICI therapies include inflammation-associated diseases, such as myocarditis, pericarditis, and vasculitis, as well as the aggravation of chronic inflammatory conditions, such as atherosclerosis with acute ischemic complications (myocardial infarction and stroke). Patients taking ICI therapies can also develop cardiac dysfunction, stress-induced cardiomyopathy (Takotsubo or apical ballooning syndrome), and heart failure without inflammatory cell infiltration of the myocardium. Atrial and ventricular arrhythmias can emerge in the setting of a systemic inflammatory milieu, myocarditis, or ischemia. Of all potential CV adverse effects, myocarditis remains of highest concern, although fatality rates have declined over time with a broadening spectrum of presentations ranging from troponin elevation of uncertain significance to smoldering, nonsevere, and severe or fulminant myocarditis. Conclusions and Relevance: Concerns for myocarditis continue to dominate the spectrum of CV toxic effects in patients receiving ICI therapy. Recommendations for management vary according to severity. Multidisciplinary collaborations remain key for managing acute toxic effects and future cancer treatment decisions, including ICI rechallenge. Ischemic heart disease constitutes the main differential diagnosis in these patients, while pericarditis can be concomitantly present, and atrial and ventricular arrhythmias can also complicate the clinical picture. Several gaps in knowledge are identified and require further research.